Is IDEXX Laboratories, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IDEXX Laboratories, Inc. moved from expensive to fair, indicating a more favorable assessment of its market position. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 60, an EV to EBITDA of 42.53, and a PEG ratio of 11.32, which suggest that while the company is priced at a premium, it may be justified given its strong performance metrics.
In comparison to its peers, IDEXX Laboratories has a higher P/E ratio than Abbott Laboratories at 18.36 and Thermo Fisher Scientific at 30.06, but is lower than Intuitive Surgical at 63.32, indicating a competitive valuation landscape. Notably, IDEXX's ROE stands at an impressive 61.71%, showcasing its efficient use of equity. Over the past year, IDEXX has returned 38.13%, significantly outperforming the S&P 500's 14.08%, reinforcing the notion that the stock is positioned well within its market.